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Several factors play a role in the cause of malabsorption in CF. Besides the enzyme deficiency 
in the secretion of the exocrine pancreas, decreased bile-salt concentration in the gut may also 
be an important factor in the fat malabsorption. The contribution to the fat absorption by 
other lipases, such as lingual lipase and gastric lipase, remains to he proved. The therapeutic 
measures are only partly effective because of the breakdown of swalled enzymes by gastric 
acid. Some improvement is reached by using a new acid-resistant coating for the enzyme 
supplement. Newly developed and essential for its success is the application of small coated 
particles to prevent retention in the stomach, and the easy breakdown of the coating in an 
alkaline solution. The treatment of the bile salt deficiency has not been successful until now. A 
trial with additional Tween 80, with the option of supplementing the detergent activity which 
was found to he successful in Crohn disease, was without marked success. 
Malabsorption is one of the more serious problems in CF. The fat and protein digestion 
and absorption and, to a lesser extent, also the carbohydrate digestion are disturbed. The 
disorder of the intraluminal digestion is caused mainly by insufficiency of the exocrine 
pancreas, in particular by the decreased secretion of bicarbonate, lipase and trypsin. 
Moreover, the digestion is disturbed by a deficiency of bile salts in the proximal gut which 
results in a reduced emulsifying capacity and a decrease in enzyme induction. 
The supposed high viscosity of the intestinal fluids may hamper the transport of digested 
products. This would explain many of the CF-related disorders, such as intestinal obstruc- 
tion and ileus symptoms and the thick unstirred water layer on the brushborder of the 
epithelium (1) .  Finally, a specific intracellular transport defect of bile salts has recently 
been suggested (2). 
In the following survey, we consider the role of these factors in CF  patients. 
Enzymes 
In the majority of C F  patients, pancreatic enzyme deficiency is such that both fat and 
protein absorption is seriously diminished. The main enzymes involved are lipase, the 
lipase-colipase complex, lingual lipase, phospholipase, and the protein and carbohydrate 
splitting enzymes. This was repeatedly shown, among others, by Wong et al. (3) using the 
pancreozymin secretin stimulation test. Their results revealed that the enzyme activity of 
lipase reached only 3 % of normal levels, whereas trypsin and chymotrypsin amounted to 
30 %. However, the usual treatment consisting of the administration of supplemental 
pancreas extract is only partly effective. Fat absorption does improve, but without 
reaching a normal level. In this connection, DiMagno et al. (4) carried out a study of 
enzyme activity in the duodenum following the administration of pancreatic extracts. In 
the distal part of the duodenum, this resulted in 22% of the administered dose for trypsin 
activity and only 3 % for the lipase activity. This was due to the fact that a great deal of the 
enzyme activity was lost in the stomach. 
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Fig.  1.  Relation between fat and bile salt 
excretion in stool during pancreatine thera- 
Recently, Gaskin et al. (5) found that an important co-factor for the fat-splitting enzyme 
lipase was deficient in cystic fibrosis patients. It turned out that the degree of deficiency of 
this colipase correlated with the steatorrhoea-sometimes even better than lipase did. 
They concluded that colipase activity was an accurate measure of the physiological 
capacity for fat digestion, especially in those patients with marginal lipase output. 
Bicarbonate 
The amount of bicarbonate from the pancreas released into the duodenum is found to be 
decreased (6, 7), due to an inadequate neutralization of gastric acid and a relative low 
duodenal pH. In CF patients with malabsorption, the bicarbonate discharge is below 10% 
of the normal value, but even patients without gastro-intestinal symptoms have an abnor- 
mal bicarbonate excretion. This will result in a decreased enzyme activity and a precipita- 
tion of glycocholic acid. 
Bile acids 
Apart from a deficiency in the enzyme activity and bicarbonate concentration in the 
duodenum the bile acid concentration in the duodenum is also decreased. The bile acid 
recirculation is disturbed, resulting in an increased faecal loss (8), probably due to a 
disorder of the absorption in the terminal ileum (2). This may lead to a reduction of the bile 
acid pool as well as a decreased excretion of bile acid in the duodenum. In addition, the 
low pH level in the duodenum due to the decreased bicarbonate excretion results in a 
precipitation of bile acid and finally some patients may have impaired liver function, which 
will result in a diminished bile acid synthesis. This low bile acid concentration in the 
duodenum will result in a hampered emulsification of fat. During a study of the effect of an 
improved preparation, we compared the effect of two different enzyme preparations on 
bile acid excretion. We found that the faecal fat excretion correlated positively with the 
faecal bile acid excretion when conventional preparations were given (Fig. I).  
Surprisingly, after the change in therapy, from the conventional enzyme preparation to 
the improved preparation, resulting in a better fat absorption, no effect could be shown on 
the bile salt excretion in the stool (Fig. 2). We concluded that bile salt malabsorption was 
not directly dependent on fat absorption and that loss of bile salts may contribute to the fat 
malabsorption, in contrast to the findings of Isenberg (9). 
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Mucus 
Freye et al. (10) noticed that in C F  patients a thick layer of mucus covered the surface of 
the brush border. Only recently, Wesley et al. (1 1) demonstrated a difference between 
normal and CF  mucus in the gut. They found that CF  mucins were enriched in glucose, 
galactose, N-acetyl glucosamine and total carbohydrate per mg protein and per oligosac- 
charide chain. They speculated that hyperglycosylation with an associated increase in 
average chain length of carbohydrate side chain would increase the equivalent hydro- 
dynamic volume of the mucin molecule and so result in enhanced viscosity and gelling. 
However, the dominant feature which controls the gelation of mucins appears to be their 
polymeric structure maintained by a disulfide-linked peptide (1 1). The possible effects of a 
thick unstirred mucus layer on intestinal absorption processes have hardly been explored 
until now. 
THERAPEUTIC CONSEQUENCES 
Pancreatic enzyme siipplementation 
Various methods have been attempted to protect enzymes against acids: coating of the 
enzymes as tablets, administration of sodium bicarbonate, blocking the production of 
gastric acid and coating of the enzymes in pH dependent microspheres. Sofar coated 
tablets have been shown to be useless as they do not disintegrate to deliver enzyme 
activity. 
Recently, a new method has been developed for coating the enzymes in order to protect 
them against gastric acid. This coating is acid-resistant, but disintegrates in an alkaline 
environment. The size of the grain is such that a smooth passage through the pylorus is 
guaranteed. We-and several other workers (12, 13) have tested this new preparation to 
see to what extent the fat absorption was improved, in comparison with a conventional 
enzyme preparation. We found a significant decrease in the stool weight, expressed in 
grams per 24 hours. The fat absorption coefficient showed an increase, from 60% in 
patients with conventional enzyme therapy to 78% with low (= 6 capsiday) and 77% with 
a high dose (=9 capsiday) of acid-resistant coated microsphere enzyme preparations (Fig. 
3 ) .  So these patients showed a much better fat absorption, although the total amount of 
supplemented enzymes expressed as enzyme activity remained almost the same. Further- 
more, it turned out that there is an optimal effect in the majority of the patients, expressed 
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as fat absorption rate, when a dose of six capsules of enzyme were given. Nine capsules a 
day did no better than six. For the protein digestion and absorption, we did not find any 
significant improvement in the treatment with acid-resistant coated enzymes. Our conclu- 
sion was that fat absorption in CF patients, not optimally correctable by the conventional 
pancreatic supplementation, was increased significantly by using this new acid-resistant 
coating. All the patients preferred the acid-resistant coated form because it was easier to 
administer, there were fewer intestinal symptoms and the fat allowance in the diet 
increased. 
Gastric acid influence on pancreatic enzymes 
Although various authors have claimed an improvement in the fat absorption as a result of 
cimetidine (14, 15); others have not been able to confirm these results (16, 17). In the case 
of treatment with pancreatic extracts, the extent of fat absorption is directly related to the 
production of gastric acid determined after maximal stimulation. However, although in o u r  
study (16) cimetidine in a low and a high dose reduced the maximal acid output significant- 
ly, the fat excretion did not alter at all (Table 1). 
Peterson et al. (18) showed in adults that the gastric pH remained below 4 during 
cimetidine therapy (300 mg with meals and at bedtime), only during the night, the pH 
raised over 4. This observation leads one to expect that supplementary enzyme prepara- 
tions during meals would be inactivated even if these patients received cimetidine. To 
Table 1 
M A 0  (n= 13) 
(rnrnolihtSD) (gi24 h t S D )  
Fecat fat (n= 13) 
Pancreatine (3-5 giday) 8.39k2.81 17.2k7.7 
Pancreatine (3-5 giday) + cimetidine (15G300 rngiday) 
Pancreatine (3-5 giday) + cimetidine (30MOO rng/day) 
6.1022.46 
4.202 2.08 
19.0+ 1 I .7 
16.9k 15.1 
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assess the effects of cimetidine in C F  patients, one has to determine the long-term actual 
pH in the stomach, which has not been studied so far. 
Dcic ' r e m  P d mu c 14s u isc 0s i t y  
We studied the extent to which normal mucus viscosity might lead to an impaired 
absorption by oral administration of a rnucolytic drug. N-acetylcystine is capable of 
breaking down the sulfide bonds and so decreasing the viscosity of the mucus. For this 
purpose, it is widely used as a diluting drug for sputum. In analogy to this we tried the 
effect of using it in the gut. We treated 12 patients with the conventional pancreatic 
enzyme therapy, and compared two week periods of 1 week with and without N- 
acetylcystine in a dose of 8 g per day. We did not observe any significant change in fat 
excretion when N-acetylcystine was given as adjuvant therapy, although there was a slight 
decrease. Since a high dose of N-acetylcystine was given, this effect is probably of little 
importance. 
Bile .snit deficiency 
King and Dubois (19, 20) both published results of the administration of a detergent 
(Tween 80) to patients with steatorrhoea related to bile salt deficiency and to control 
patients receiving cholestyramine, a bile salt sequestering agent. Both described a positive 
effect on the fat excretion in the stool. We studied the effect of Tween 80 administration (6 
gramiday) to CF patients with steatorrhoea and increased bile salt loss in the stool. The 
results were disappointing, the fat excretion and the bile salt loss in the stool did not 
change at all, even with a high dose of Tween 80 (Table 2). 
A definite conclusion cannot be drawn from these preliminary results, regarding the 
effect of bile salt; acid precipitation is a possibility, but not studied until now. 
In  summary, we have discussed four items. We stressed that enzymes and bicarbonate 
concentration are deficient, enzyme preparations are improving, while cimetidine as a 
therapy is debatable. The bile salt deficiency remains a problem, some C F  patients lose 
much of  their bile salts in t h e  stool. It is possible that bile salt supplementation in a certain 
form will improve fat malabsorption. Finally, the intestinal mucus also seems to be 
abnormal, but treatment with a mucus solvent was not effective in our experience. 
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